Extended-release phentermine/topiramate,
does it really help with Reduction in body weight and waist circumference over 56 weeks in adults with obesity using diet and exercise?
research showsExtended-release phentermine/topiramate is rated B for reducing body weight and waist circumference over 56 weeks when combined with lifestyle treatment in adults with obesity. In the 2,487-participant CONQUER trial, 56-week weight change was -1.2% with placebo, -7.8% with the mid dose, and -9.8% with the top dose. In the 1,267-participant EQUIP trial, changes were -1.6%, -5.1%, and -10.9%. Roughly 10% weight loss at 56 weeks is a strong direct clinical outcome, but every pivotal trial focused on VIVUS's branded extended-release combination and no cardiovascular hard-outcome trial exists. Consistency with other prescription obesity drugs supports B rather than C, but these limitations place it at the lower end of B with 73 points.
ads claimPromotion can turn mean losses of 8% to 10% into every user's result, permanent maintenance after stopping, and prevention of cardiovascular disease. The measured effect is an average during continued treatment with diet and exercise, with individual nonresponse and discontinuation; cardiovascular hard-outcome benefit remains unestablished.
Useful facts when choosing a product
- Qsymia is a fixed-dose extended-release prescription combination of phentermine and topiramate that is titrated from a low dose, with continuation or gradual discontinuation assessed according to weight response at specified time points.
- Topiramate exposure is associated with congenital malformations including oral clefts, so pregnancy is contraindicated; patients who can become pregnant require a negative test before treatment and monthly testing with effective contraception.
- Paresthesia, dry mouth, constipation, insomnia, and altered taste can occur, as can attention, memory, or language problems, mood changes, metabolic acidosis, and kidney stones; abrupt withdrawal from a high dose can increase seizure risk.
- Cardiovascular status, including increased heart rate, requires review, and pregnancy, glaucoma, hyperthyroidism, and recent monoamine oxidase inhibitor use are important contraindications. Blood pressure may fall with weight loss, but pulse and blood pressure still require individual monitoring.
What the research actually shows
CONQUER randomized 2,487 adults with BMI 27 to 45 kg/m² and comorbidities to placebo, 7.5/46 mg, or 15/92 mg, with lifestyle intervention in every group. At 56 weeks, the two doses produced approximately 6.6 to 8.6 percentage points more weight loss than placebo. EQUIP assigned 1,267 adults with BMI at least 35 kg/m² to a reduced-calorie diet plus placebo or two doses and reported 10.9% loss and a significant waist reduction with the top dose. SEQUEL enrolled 676 volunteers from selected CONQUER sites and confirmed sustained loss through 108 weeks, but it was not an independent long-term outcome for the full randomized population. None of these trials used cardiovascular events as the primary powered outcome.
Why this is classified as B (73)
B. Large 56-week trials involving 2,487 CONQUER and 1,267 EQUIP participants reproduced roughly 10% weight loss and reduced waist circumference. Weight loss is a direct clinical outcome rather than a surrogate, and consistency with other prescription obesity drugs supports B. However, every pivotal trial focused on VIVUS's branded extended-release combination and no cardiovascular hard-outcome trial exists, yielding lower B with 73 points. Teratogenicity, cognitive and sensory effects, heart rate, and contraindications remain serious safety issues separate from efficacy.
Counterpoint. Unlike short-term phentermine monotherapy, this combination has genuine large 56-week randomized trials and should not be reduced to the same C grade as a long-term monotherapy claim. Prescribing still requires assessment of pregnancy potential, cardiovascular and mental-health status, and early response.
Rejudgment record. Cross-check revision — Weight loss is a direct clinical outcome rather than a surrogate, and consistency with existing prescription obesity drugs—naltrexone/bupropion (ID 709), orlistat, liraglutide, and tirzepatide, all rated B—supports B. However, every pivotal trial studied the manufacturer's (VIVUS) branded extended-release combination, and no cardiovascular hard-outcome trial exists, so the score was adjusted to the lower end of B (73).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction in body weight over 56 weeks in adults with obesity using diet and exercise | B | Two large placebo-controlled trials reproduced approximately 8% to 11% loss with the mid and top doses. |
| Reduction in waist circumference over 56 weeks in adults with obesity using diet and exercise | B | Fifty-six-week trials including EQUIP found significantly greater waist reduction, particularly with the top dose. |
| Reduction of cardiovascular events with extended-release phentermine/topiramate | ? | Weight and metabolic variables improved, but no efficacy trial has established effects on myocardial infarction, stroke, or death. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gadde KM et al. 2011 CONQUER | Fifty-six-week multicenter randomized double-blind placebo-controlled phase 3 trial | 2,448 | VIVUS | Percentage body-weight change and proportion achieving at least 5% loss | At 56 weeks, weight changed by -1.2%, -7.8%, and -9.8%, while at least 5% loss occurred in 21%, 62%, and 70%. | Key large direct weight trial |
| Allison DB et al. 2012 EQUIP | Fifty-six-week randomized double-blind placebo-controlled trial | 1,267 | VIVUS | Percentage weight loss, at least 5% loss, and waist circumference | Weight changed by -1.6%, -5.1%, and -10.9%, and the top dose significantly reduced waist circumference. | Replicated direct 56-week trial in a separate cohort |
| Garvey WT et al. 2012 SEQUEL | Fifty-two-week double-blind placebo-controlled extension retaining the original randomization | 676 | VIVUS | Sustained weight loss and metabolic variables through 108 weeks | At 108 weeks, weight changed by -1.8%, -9.3%, and -10.5%. | Supportive durability evidence limited by volunteer selection |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Extended-release phentermine/topiramate x 56-week reductions in body weight and waist circumference in adults with obesity — Evidence Grade B·73. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/phentermine-topiramate-er-56-week-weight-waist-reduction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.